iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
14 août 2023 16h15 HE
|
iBio, Inc.
– AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets – BRYAN, Texas and SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
27 juin 2023 08h00 HE
|
iBio, Inc.
– Board appointments solidify management team to lead iBio’s AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the...
iBio Forges Research Collaboration with the National Institutes of Health
12 juin 2023 16h15 HE
|
iBio, Inc.
– NIH to evaluate iBio’s patented AI-driven epitope steering platform for Lassa fever vaccine development – BRYAN, Texas and SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)...
iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
06 juin 2023 08h00 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced the expansion of its AI-powered technology stack with the launch of...
iBio to Participate in the JMP Securities Life Sciences Conference
09 mai 2023 16h30 HE
|
iBio, Inc.
BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its...
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform
04 avr. 2023 16h05 HE
|
iBio, Inc.
BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given...
iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing
31 mars 2023 08h10 HE
|
iBio, Inc.
– Immuno-oncology candidate discovered using iBio’s AI epitope steering platform – – Expands Treg depletion franchise beyond IBIO-101 – BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc....
iBio Announces MUC16 as its Latest Immune-Oncology Target Program
16 févr. 2023 16h48 HE
|
iBio, Inc.
- Company has directed antibodies against a specific region of MUC16 - - Potentially offers a differentiated and effective tool in the fight against cancer - BRYAN, Texas, Feb. 16, 2023 (GLOBE...
iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine
05 janv. 2023 08h00 HE
|
iBio, Inc.
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United...
iBio Announces Closing of $3.5 Million Underwritten Public Offering
09 déc. 2022 16h05 HE
|
iBio, Inc.
BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its...